Cassava Sciences CEO Remi Barbier on Monday shifted his defense of the company’s embattled treatment for Alzheimer’s disease: The drug is safe, he said, therefore the Food and Drug Administration shouldn’t interfere with the company’s plan to start late-stage clinical trials.
Barbier, speaking via a prerecorded video during an investor conference sponsored by the investment bank H.C. Wainwright, also backtracked from claims made by Cassava that an ongoing mid-stage study showed its drug had improved the cognition of patients with Alzheimer’s.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
